CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 220 enrolled
Drug / intervention
Empagliflozin 25 MG +1 moredrug
Likely dose
Empagliflozin 25 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06187285
NCT06187285N/ACompleted

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia: Randomised Control

Medanta, The Medicity, India·interventional·Posted Jan 2, 2024·Updated Jun 13, 2025

In Brief

A clinical study evaluating Empagliflozin 25 MG and Sitagliptin 100mg for Type 2 Diabetes. Completed, enrolled 220 participants across 1 site.

Detailed Summary

Clinical guidelines from professional organizations have recommended the use of multidose insulin regimens as the preferred therapy for glycaemic control in patients admitted to hospital in a non-intensive-careunit setting. The use of a basal-bolus regimen with a once daily basal insulin and rapid-acting insulin analogs before meals has been shown to improve glycaemic control and to reduce the rate of hospital complications in general medical and surgical patients with type 2 diabetes.The basal-bolus regimen however is labour intensive, requiring several insulin injections, and is associated with a high risk of hypoglycaemia. Hypoglycaemia has been reported in 12% to 32% of patients in general medicine and surgery with type 2 diabetes treated with basal-bolus insulin regimens.Because of these limitations, alternative treatment regimens are needed that could improve glycaemic control and clinical outcomes, while facilitating care and minimising the risk of hypoglycaemia in patients with diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesIndia

Timeline

N/ACompletedFinished
202420252026
First PostedJan 2, 2024
Enrollment StartJan 1, 2024
Primary CompletionMay 1, 2025
Study CompletionJun 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.5 years ago

Interventions

Empagliflozin 25 MGdrug

Patient will get Empagliflozin 25

Sitagliptin 100mgdrug

Patient will get Sitagliptin 100 mg